Pancreatic Cancer Research

ResearcherOita UniversityActive in the last 2 years

Akiko Todaka

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7308-5960; OpenAlex author ID A5015481734. Sources: OpenAlex.

Their work

Papers
27 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
110
Papers, trials and grants by year

2017: 1 paper · 2018: 1 paper · 2019: 4 papers · 2020: 3 papers · 2021: 2 papers · 2022: 6 papers · 2023: 6 papers · 2024: 1 paper · 2025: 3 papers

Papers 27

  1. Depth of response in patients with locally advanced pancreatic cancer treated with first-line chemotherapy: A supplementary analysis of JCOG1407. Co-author DOI 10.1016/j.pan.2025.02.005↗
  2. Outcomes of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in patients with early recurrent pancreatic cancer after adjuvant S-1 treatment: A propensity sco… Co-author DOI 10.1016/j.pan.2025.08.017↗
  3. Impact of biliary drainage for unresectable pancreatic cancer treated with nanoliposomal irinotecan with fluorouracil and folinic acid: retrospective results f… Co-author DOI 10.1186/s12885-025-14992-2↗
  4. Two Japanese families with familial pancreatic cancer with suspected pathogenic variants of CDKN2A: a case report. Co-author DOI 10.1186/s13053-024-00283-7↗
  5. Long-term adjuvant chemotherapy after resection for pancreatic cancer patients with positive peritoneal lavage cytology. Co-author DOI 10.1007/s00423-023-02906-4↗
  6. A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407). Co-author DOI 10.1016/j.ejca.2022.12.014↗
  7. Genetic medicine in companion diagnostics of germline BRCA testing of Japanese pancreatic cancer patients. First author DOI 10.1038/s10038-022-01097-y↗
  8. Effect of systemic inflammatory response on induction chemotherapy followed by chemoradiotherapy for locally advanced pancreatic cancer: an exploratory subgrou… Co-author DOI 10.1093/jjco/hyad044↗
  9. Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil/leucovorin. First author DOI 10.1186/s12885-023-10542-w↗
  10. FOLFIRINOX in Pancreatic Cancer: Risk Factors for Febrile Neutropenia and Severe Neutropenia - Nationwide Study Analysis. Co-author DOI 10.21873/anticanres.16601↗
  11. The prognostic impact of ABO blood type in pancreatic cancer: Relevance to adjuvant chemotherapy. Co-author DOI 10.1002/jhbp.1152↗
  12. Effectiveness and safety of gemcitabine plus nab-paclitaxel in elderly patients with advanced pancreatic cancer: a single-center retrospective cohort study. First author DOI 10.1007/s10637-022-01221-x↗
  13. Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic Cancer. Co-author DOI 10.1093/oncolo/oyac157↗
  14. The Association Between Neoadjuvant Therapy and Pathological Outcomes in Pancreatic Cancer Patients After Resection: Prognostic Significance of Microscopic Ven… Co-author DOI 10.1245/s10434-022-11628-8↗
  15. ASO Author Reflections: Neoadjuvant Therapy for Pancreatic Cancer may Reduce Microscopic Venous Invasion, Which is an Independent Prognostic Factor Associated … Co-author DOI 10.1245/s10434-022-11662-6↗
  16. Postoperative Treatment of Resectable Pancreatic Cancer With Positive Peritoneal Lavage Cytology: A Multicentre Retrospective Study. Co-author DOI 10.21873/anticanres.15547↗
  17. Predictive factors of survival in patients with borderline resectable pancreatic cancer who received neoadjuvant therapy. Co-author DOI 10.1016/j.pan.2021.08.009↗
  18. Randomized phase II study of chemoradiotherapy with versus without induction chemotherapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group… Co-author DOI 10.1093/jjco/hyaa198↗
  19. Prognostic impact of abutment to the branches of the superior mesenteric artery in borderline resectable pancreatic cancer. Co-author DOI 10.1007/s00423-020-01970-4↗
  20. FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: A subset analysis of data from a nationwide multicenter observational study in Japan. Co-author DOI 10.1016/j.pan.2020.07.006↗
  21. FOLFIRINOX for Recurrent Pancreatic Cancer After Pancreatic Resection: A Secondary Analysis of the Nationwide Multicenter Observational Study Conducted by the … Co-author DOI 10.1097/mpa.0000000000001692↗
  22. Prognostic role of the length of tumour-vein contact at the portal-superior mesenteric vein in patients having surgery for pancreatic cancer. Co-author DOI 10.1002/bjs.11328↗
  23. FOLFIRINOX for locally advanced pancreatic cancer: Results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japa… Co-author DOI 10.1016/j.pan.2019.01.001↗
  24. Impact of UGT1A1 genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing FOLFIRINOX. First author DOI 10.1111/cas.13883↗
  25. Influence of initial dose intensity on efficacy of FOLFIRINOX in patients with advanced pancreatic cancer. Co-author DOI 10.18632/oncotarget.26633↗
  26. Nationwide Multicenter Observational Study of FOLFIRINOX Chemotherapy in 399 Patients With Unresectable or Recurrent Pancreatic Cancer in Japan. Co-author DOI 10.1097/mpa.0000000000001049↗
  27. Gastrojejunostomy versus duodenal stent placement for gastric outlet obstruction in patients with unresectable pancreatic cancer. Co-author DOI 10.1016/j.pan.2017.09.011↗

Closest collaborators

The 25 strongest of 110 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Masato Ozaka · 12 shared papers, 2018–2025 · strength 1.36
  2. Satoshi Kobayashi · 11 shared papers, 2018–2025 · strength 1.27
  3. Teiichi Sugiura · 9 shared papers, 2017–2023 · strength 1.16
  4. Ryo Ashida · 8 shared papers, 2019–2024 · strength 1.15
  5. Nobumasa Mizuno · 10 shared papers, 2018–2023 · strength 1.01
  6. Naohiro Okano · 9 shared papers, 2018–2025 · strength 1.00
  7. Katsuhiko Uesaka · 7 shared papers, 2019–2023 · strength 0.96
  8. Katsuhisa Ohgi · 7 shared papers, 2019–2023 · strength 0.96
  9. Akira Fukutomi · 11 shared papers, 2017–2021 · strength 0.96
  10. Junji Furuse · 7 shared papers, 2021–2025 · strength 0.95
  11. Makoto Ueno · 7 shared papers, 2019–2025 · strength 0.90
  12. Kentaro Yamazaki · 6 shared papers, 2017–2023 · strength 0.83
  13. Keiko Kamei · 7 shared papers, 2018–2025 · strength 0.74
  14. Masafumi Ikeda · 5 shared papers, 2021–2025 · strength 0.72
  15. Hirofumi Yasui · 4 shared papers, 2017–2023 · strength 0.53
  16. Yukiyasu Okamura · 4 shared papers, 2019–2023 · strength 0.51
  17. Mihoko Yamada · 3 shared papers, 2022–2023 · strength 0.50
  18. Kentaro Sudo · 5 shared papers, 2018–2023 · strength 0.49
  19. Hideyuki Hayashi · 5 shared papers, 2018–2023 · strength 0.48
  20. Takeshi Kawakami · 3 shared papers, 2022–2023 · strength 0.47
  21. Noritoshi Kobayashi · 5 shared papers, 2018–2023 · strength 0.46
  22. Hiroshi Ishii · 4 shared papers, 2021–2023 · strength 0.44
  23. Nao Fujimori · 3 shared papers, 2023–2025 · strength 0.44
  24. Hiroshi Imaoka · 3 shared papers, 2022–2025 · strength 0.41
  25. Taro Shibuki · 2 shared papers, 2025 · strength 0.37

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.